-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, UXRe4dz35KhhxVsiAToFwmk+a1Z38v4p184Y4sxPs9EGAu/GikvVYLPFzSpCaDso go4JcYqQu7nMrQEyogvDgQ== 0000903100-01-000016.txt : 20010207 0000903100-01-000016.hdr.sgml : 20010207 ACCESSION NUMBER: 0000903100-01-000016 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20010205 ITEM INFORMATION: FILED AS OF DATE: 20010206 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CYTOGEN CORP CENTRAL INDEX KEY: 0000725058 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 222322400 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: SEC FILE NUMBER: 000-14879 FILM NUMBER: 1526332 BUSINESS ADDRESS: STREET 1: 600 COLLEGE RD EAST CN 5308 CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: 6099878200 MAIL ADDRESS: STREET 1: 600 COLLEGE RD EAST CN 5308 STREET 2: 600 COLLEGE RD EAST CN 5308 CITY: PRINCETON STATE: NJ ZIP: 08540 8-K 1 0001.txt CYTOGEN CORPORATION SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 -------------------------------------------- FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 5, 2001 ---------------- CYTOGEN CORPORATION ---------------------------------------------- (Exact Name of Registrant as Specified in Charter) Delaware 000-14879 22-2322400 - ---------------------------- ------------------------ ------------------- (State or Other Jurisdiction (Commission File Number) (I.R.S. Employer of Incorporation) Identification No.) 600 College Road East, CN 5308, Princeton, NJ 08540 - -------------------------------------------------------------------------------- (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code: (609) 750-8200 -------------- ITEM 5. OTHER EVENTS. On October 9, 2000, Cytogen Corporation, a Delaware corporation (the "Company") entered into an Equity Financing Facility (the "Facility") under the terms of a Common Stock Purchase Agreement (the "Agreement") with Acqua Wellington North American Equities Fund, Ltd. ("Acqua Wellington"). Under the terms of the Agreement, the Company may, at its sole discretion and from time to time over a 20 month period from such date, sell shares of its Common Stock to Acqua Wellington at a small discount to market price, as determined prior to each such sale. The Facility is not subject to any minimum takedown requirements and provides for the sale of up to $70 million in registered shares of the Company's Common Stock. On February 5, 2001, the Company consummated a draw down on the Facility through the issuance of 1,276,557 shares of its Common Stock to Acqua Wellington for an aggregate purchase price of $6,500,000. ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS. (a) Exhibits. -------- Exhibit No. Description ----------- ----------- 10.1 Common Stock Purchase Agreement (incorporated by reference to the Company's Current Report on Form 8-k, filed with the Securities and Exchange Commission on October 12, 2000. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this current report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. CYTOGEN CORPORATION By: /s/ Catherine M. Verna ---------------------------------- Catherine M. Verna, Esq. Vice President and General Counsel Dated: February 5, 2001 -----END PRIVACY-ENHANCED MESSAGE-----